MARKETS
RELIANCETCSHDFCBANKINFYICICIBANKSBINITCLTBHARTIARTLAXISBANKMARUTISUNPHARMA

Wockhardt Ltd.

WOCKPHARMA · Pharmaceuticals & Drugs
₹1,855.50
▼ 21.70 (-1.16%)
Market dataas of 22 Oct 2026, 12:00 am IST
52-week range · NSE23.4% below its high
Low ₹1,086.70High ₹2,422.30
70.7% above its low · +38.6% over 52 weeks
Today’s range · NSE₹1,846.00 – ₹1,899.90
Low ₹1,846.00High ₹1,899.90
2.9% between low and high
P/E against its industry447% above the industry median
WOCKPHARMA141.4
Industry median25.9
Pharmaceuticals & Drugs · median of profitable companies in the industry
Market cap₹30,059 Cr
Current price₹1,855.50
Volume · NSE4.57 L
52w High / Low · NSE₹2,422 / ₹1,087
Stock P/E141.4
Industry P/E25.9
Book value₹304.14
Dividend yield—
ROCE6.8%
ROE4.3%
Debt / Equity0.43
EPS (TTM)₹13.12
Face value₹5

Price

Daily candles · NSE
▲ ₹516.5 (38.57%)over 1Y
1,5002,0002,5002.3CrOct 25Jan 26Apr 26Jul 26Oct 26

What the numbers say

  • Low return on equity: 3-year ROE -3.8%.
  • Comfortable leverage: debt-to-equity of 0.43.
  • Sales growth muted at 8.4% over 3 years.
  • Weak cash conversion (CFO/OP 0.44).
  • Trades above its industry P/E (141.4 vs 25.9).

Generated automatically from reported financials. These are observations, not a recommendation to buy or sell.

  • Board Meeting

    Quarterly Results

  • Board Meeting

    Audited Results Inter alia, to consider and approve:- (i) raising of funds by issue of Equity Shares, Equity Shares through depository receipt including Global Depository Receipts , American Depository Receipts , Foreign Currency Convertible Bonds , Fully…

Company announcements as filed with the exchanges. Reproduced for information — not a view or a recommendation.

Profit & Loss · ₹ croreFY26FY25FY24FY23FY22
Net Sales3,3733,0122,7982,6513,230
Other income137628312220
Total Income3,5103,0742,8812,7733,250
Expenditure2,7472,6192,7592,5502,932
Operating Profit763455122223318
Interest213254305302299
Depreciation227217223251247
Profit before tax238-16-420-624-411
Tax394152-3-132
Net Profit199-57-472-621-279
EPS (₹)13.12-3.02-32.05-38.79-20.24
Net margin %5.9-1.9-16.9-23.4-8.6

Consolidated figures, as filed with the exchanges. Newest year first. EPS for FY21 is not shown: the value supplied does not agree with the number of shares the company reported for that year, and we would rather show nothing than a figure we cannot reconcile.

Balance Sheet · ₹ croreFY26FY25FY24FY23FY22
Equity capital8181777272
Reserves4,8464,2613,2693,2663,759
Net worth4,9274,3423,3463,3383,831
Total sources6,9566,0584,8234,2165,008
Net block2,7912,7362,8813,0423,462
Capital work in progress2,3792,0331,7221,5391,342
Investments683670283286277
Inventory887725640658769
Debtors588661618797918
Cash & bank250191529124406
Book value (₹)304.14268.02217.27231.81266.04

Consolidated figures, as filed with the exchanges. Newest year first.

Cash Flow · ₹ croreFY26FY25FY24FY23FY22
From operations390-22219153413
From investing-241-783-137-125-201
From financing-54409334-315-71
Net change in cash95-396416-287141
Free cash flow149-8058228212
Closing cash21711250590370

Consolidated figures, as filed with the exchanges. Newest year first.

RatiosFY26FY25FY24FY23FY22
ROCE %6.84.1-2.1-5.9-2.0
ROE %4.3-1.5-14.1-17.3-7.8
PAT margin %5.1-1.5-13.1-14.5-5.4
EBIT margin %11.66.2-3.2-7.5-2.2
Debt / equity0.430.430.630.570.49
Current ratio1.611.210.740.560.76
Interest cover2.120.94-0.38-1.07-0.37
Sales growth %12.07.65.5-17.919.3
Dividend per share (₹)0.000.000.000.000.00

Consolidated figures, as filed with the exchanges. Newest year first.

Frequently asked

Wockhardt Ltd. (WOCKPHARMA) last traded at ₹1,855.50 on the NSE, down +1.16% on the session. Prices on this page are indicative and for information only.

Wockhardt Ltd. has traded between ₹1,086.70 and ₹2,422.30 over the last 52 weeks on the NSE.

Wockhardt Ltd. has a market capitalisation of about ₹30,059 crore.

Wockhardt Ltd. trades at a P/E of 141.4, against an industry P/E of 25.9.

Open a trading and Demat account with Labdhi — it is fully digital with paperless KYC — then place a buy order for WOCKPHARMA from the Labdhi app or web platform.

Yes. You can invest in equities in a staggered manner through Labdhi. Speak to your Labdhi adviser about a plan suited to your goals and risk profile.

Who is actually trading it

Delivery against churn, the deals big enough to be reported, what the insiders did, and the benchmarks that hold Wockhardt Ltd..

Loading trading activity…

Exchange filings and end-of-day data, not a live feed. Bulk, block and insider records are published by the exchanges when a threshold is crossed, so they show reportable activity only. For information, not a recommendation to deal, and not a view on any person named above.

Disclosures. Investment in securities market are subject to market risks. Read all the related documents carefully before investing.

Registration granted by SEBI, membership of BASL (in case of IAs) and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

Prices and data on this page are indicative and for information only. Nothing here is investment advice or a recommendation to buy or sell any security. Investors should consider their own objectives, financial situation and risk profile, and may wish to seek independent advice, before investing.

Figures are as reported by the company; consolidated where available. Errors and omissions excepted.

L. F. C. Securities Pvt. Ltd. · Member BSE, NSE, MCX · SEBI Stock Broker INZ000170736 · CDSL IN-DP-281-2016 · AMFI ARN-78991 · Investment Adviser (Non-Individual) INA000011617 · Compliance Officer: Mr. Santosh Patil · santoshp@labdhi.in · 022-35006933 · Investor Grievances: investorgreve@labdhi.in